VivoSeq
Infectious Disease

Cerebral Toxoplasmosis

4

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

Cerebral Toxoplasmosis is an early-stage landscape with 4 programs across 1 company. The most active players are Eastern Cooperative Oncology Group. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

Eastern Cooperative Oncology Group

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Trial Status

3

clinical trials

Completed2 · 67%
Recruiting1 · 33%

Clinical Trials

Trial Activity

Primary Prophylaxis of Cerebral Toxoplasmosis in HIV-Infected Patients
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000643·150 enrolled
Treatment of Cerebral Toxoplasmosis in HIV/AIDS
Completed·Department of Medical Services Ministry of Public Health of Thailand·Phase 4·NCT00367081·30 enrolled
Dexamethasone for Cerebral Toxoplasmosis
Recruiting·UUniversitas Padjadjaran·Phase 2·NCT04341155·138 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)